A Phase I, Single-Blind, Placebo-Controlled, Randomized, Parallel-Design Study to Evaluate the Possible Effects of Age, Gender, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of TAK-536 in Healthy Adult Subjects